Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:56 UTC |
---|
HMDB ID | HMDB0015321 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Clindamycin |
---|
Description | Clindamycin, also known as cleocin or 7-CDL, belongs to the class of organic compounds known as proline and derivatives. Proline and derivatives are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. Clindamycin is a drug. Clindamycin is a semisynthetic lincosamide antibiotic that has largely replaced lincomycin due to an improved side effect profile. Clindamycin is a very strong basic compound (based on its pKa). In humans, clindamycin is involved in clindamycin action pathway. Orally and parenterally administered clindamycin has been associated with severe colitis (pseudomembranous colitis) which may result in patient death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Clindamycin is a potentially toxic compound. Rapidly absorbed after oral administration with peak serum concentrations observed after about 45 minutes. Oral; topical; parenteral (intramuscular, intravenous). Systemic/vaginal clindamycin inhibits protein synthesis of bacteria by binding to the 50S ribosomal subunits of the bacteria. |
---|
Structure | CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9?,10-,11+,12?,13+,14-,15-,16-,18-/m1/s1 |
---|
Synonyms | Value | Source |
---|
7(S)-Chloro-7-deoxylincomycin | ChEBI | 7-CDL | ChEBI | Cleocin | ChEBI | Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranoside | ChEBI | CLDM | Kegg | Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-a-D-galacto-octopyranoside | Generator | Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside | Generator | Clindamycin phosphate | HMDB | 7 Chloro 7 deoxylincomycin | HMDB | Clindamycin monohydrochloride, monohydrate | HMDB | Hydrochloride, clindamycin | HMDB | Monohydrate clindamycin monohydrochloride | HMDB | 7-Chloro-7-deoxylincomycin | HMDB | Chlolincocin | HMDB | Clindamycin hydrochloride | HMDB | Monohydrochloride, clindamycin | HMDB | Monohydrochloride, monohydrate clindamycin | HMDB | Chlorlincocin | HMDB | Clindamycin monohydrochloride | HMDB | Dalacin C | HMDB |
| Show more...
---|
Chemical Formula | C18H33ClN2O5S |
---|
Average Molecular Weight | 424.983 |
---|
Monoisotopic Molecular Weight | 424.179870573 |
---|
IUPAC Name | (2S,4R)-N-{2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl}-1-methyl-4-propylpyrrolidine-2-carboxamide |
---|
Traditional Name | clindamycin |
---|
CAS Registry Number | 18323-44-9 |
---|
SMILES | CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O |
---|
InChI Identifier | InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9?,10-,11+,12?,13+,14-,15-,16-,18-/m1/s1 |
---|
InChI Key | KDLRVYVGXIQJDK-NOWPCOIGSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as proline and derivatives. Proline and derivatives are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Amino acids, peptides, and analogues |
---|
Direct Parent | Proline and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Proline or derivatives
- Alpha-amino acid amide
- Glycosyl compound
- S-glycosyl compound
- Pyrrolidine carboxylic acid or derivatives
- Pyrrolidine-2-carboxamide
- Monosaccharide
- Oxane
- N-alkylpyrrolidine
- Monothioacetal
- Pyrrolidine
- Carboxamide group
- Secondary alcohol
- Secondary carboxylic acid amide
- Tertiary amine
- Tertiary aliphatic amine
- Sulfenyl compound
- Organoheterocyclic compound
- Azacycle
- Polyol
- Oxacycle
- Organic nitrogen compound
- Organosulfur compound
- Organooxygen compound
- Organonitrogen compound
- Organochloride
- Organohalogen compound
- Alkyl chloride
- Alcohol
- Organic oxygen compound
- Carbonyl group
- Amine
- Organopnictogen compound
- Organic oxide
- Alkyl halide
- Hydrocarbon derivative
- Aliphatic heteromonocyclic compound
|
---|
Molecular Framework | Aliphatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 142 °C (hydrochloride salt) | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 3.1 g/L | Not Available | LogP | 1.6 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Clindamycin,1TMS,isomer #1 | CCC[C@@H]1C[C@@H](C(=O)NC(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C)[C@@H](O)[C@H]2O)N(C)C1 | 2930.3 | Semi standard non polar | 33892256 | Clindamycin,1TMS,isomer #2 | CCC[C@@H]1C[C@@H](C(=O)NC(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O[Si](C)(C)C)[C@H]2O)N(C)C1 | 2935.3 | Semi standard non polar | 33892256 | Clindamycin,1TMS,isomer #3 | CCC[C@@H]1C[C@@H](C(=O)NC(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O[Si](C)(C)C)N(C)C1 | 2934.7 | Semi standard non polar | 33892256 | Clindamycin,1TMS,isomer #4 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[Si](C)(C)C)N(C)C1 | 2931.3 | Semi standard non polar | 33892256 | Clindamycin,2TMS,isomer #1 | CCC[C@@H]1C[C@@H](C(=O)NC(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H]2O)N(C)C1 | 2932.0 | Semi standard non polar | 33892256 | Clindamycin,2TMS,isomer #2 | CCC[C@@H]1C[C@@H](C(=O)NC(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C)[C@@H](O)[C@H]2O[Si](C)(C)C)N(C)C1 | 2906.3 | Semi standard non polar | 33892256 | Clindamycin,2TMS,isomer #3 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C)[C@@H](O)[C@H]2O)[Si](C)(C)C)N(C)C1 | 2942.6 | Semi standard non polar | 33892256 | Clindamycin,2TMS,isomer #4 | CCC[C@@H]1C[C@@H](C(=O)NC(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O[Si](C)(C)C)[C@H]2O[Si](C)(C)C)N(C)C1 | 2931.4 | Semi standard non polar | 33892256 | Clindamycin,2TMS,isomer #5 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O[Si](C)(C)C)[C@H]2O)[Si](C)(C)C)N(C)C1 | 2936.8 | Semi standard non polar | 33892256 | Clindamycin,2TMS,isomer #6 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O[Si](C)(C)C)[Si](C)(C)C)N(C)C1 | 2934.3 | Semi standard non polar | 33892256 | Clindamycin,3TMS,isomer #1 | CCC[C@@H]1C[C@@H](C(=O)NC(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H]2O[Si](C)(C)C)N(C)C1 | 2926.3 | Semi standard non polar | 33892256 | Clindamycin,3TMS,isomer #2 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H]2O)[Si](C)(C)C)N(C)C1 | 2960.0 | Semi standard non polar | 33892256 | Clindamycin,3TMS,isomer #3 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C)[C@@H](O)[C@H]2O[Si](C)(C)C)[Si](C)(C)C)N(C)C1 | 2955.5 | Semi standard non polar | 33892256 | Clindamycin,3TMS,isomer #4 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O[Si](C)(C)C)[C@H]2O[Si](C)(C)C)[Si](C)(C)C)N(C)C1 | 2958.9 | Semi standard non polar | 33892256 | Clindamycin,4TMS,isomer #1 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H]2O[Si](C)(C)C)[Si](C)(C)C)N(C)C1 | 3008.8 | Semi standard non polar | 33892256 | Clindamycin,4TMS,isomer #1 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H]2O[Si](C)(C)C)[Si](C)(C)C)N(C)C1 | 3004.5 | Standard non polar | 33892256 | Clindamycin,4TMS,isomer #1 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H]2O[Si](C)(C)C)[Si](C)(C)C)N(C)C1 | 3283.8 | Standard polar | 33892256 | Clindamycin,1TBDMS,isomer #1 | CCC[C@@H]1C[C@@H](C(=O)NC(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H]2O)N(C)C1 | 3164.1 | Semi standard non polar | 33892256 | Clindamycin,1TBDMS,isomer #2 | CCC[C@@H]1C[C@@H](C(=O)NC(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]2O)N(C)C1 | 3164.0 | Semi standard non polar | 33892256 | Clindamycin,1TBDMS,isomer #3 | CCC[C@@H]1C[C@@H](C(=O)NC(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O[Si](C)(C)C(C)(C)C)N(C)C1 | 3166.9 | Semi standard non polar | 33892256 | Clindamycin,1TBDMS,isomer #4 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[Si](C)(C)C(C)(C)C)N(C)C1 | 3175.6 | Semi standard non polar | 33892256 | Clindamycin,2TBDMS,isomer #1 | CCC[C@@H]1C[C@@H](C(=O)NC(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]2O)N(C)C1 | 3366.7 | Semi standard non polar | 33892256 | Clindamycin,2TBDMS,isomer #2 | CCC[C@@H]1C[C@@H](C(=O)NC(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H]2O[Si](C)(C)C(C)(C)C)N(C)C1 | 3359.5 | Semi standard non polar | 33892256 | Clindamycin,2TBDMS,isomer #3 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H]2O)[Si](C)(C)C(C)(C)C)N(C)C1 | 3405.6 | Semi standard non polar | 33892256 | Clindamycin,2TBDMS,isomer #4 | CCC[C@@H]1C[C@@H](C(=O)NC(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]2O[Si](C)(C)C(C)(C)C)N(C)C1 | 3363.9 | Semi standard non polar | 33892256 | Clindamycin,2TBDMS,isomer #5 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]2O)[Si](C)(C)C(C)(C)C)N(C)C1 | 3386.5 | Semi standard non polar | 33892256 | Clindamycin,2TBDMS,isomer #6 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N(C)C1 | 3392.4 | Semi standard non polar | 33892256 | Clindamycin,3TBDMS,isomer #1 | CCC[C@@H]1C[C@@H](C(=O)NC(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]2O[Si](C)(C)C(C)(C)C)N(C)C1 | 3506.8 | Semi standard non polar | 33892256 | Clindamycin,3TBDMS,isomer #2 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]2O)[Si](C)(C)C(C)(C)C)N(C)C1 | 3593.6 | Semi standard non polar | 33892256 | Clindamycin,3TBDMS,isomer #3 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H]2O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N(C)C1 | 3595.2 | Semi standard non polar | 33892256 | Clindamycin,3TBDMS,isomer #4 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]2O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N(C)C1 | 3579.7 | Semi standard non polar | 33892256 | Clindamycin,4TBDMS,isomer #1 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]2O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N(C)C1 | 3779.4 | Semi standard non polar | 33892256 | Clindamycin,4TBDMS,isomer #1 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]2O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N(C)C1 | 3695.5 | Standard non polar | 33892256 | Clindamycin,4TBDMS,isomer #1 | CCC[C@@H]1C[C@@H](C(=O)N(C(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]2O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N(C)C1 | 3648.1 | Standard polar | 33892256 |
| Show more...
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Clindamycin GC-MS (Non-derivatized) - 70eV, Positive | splash10-004i-9834100000-dda83549a397e8777758 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Clindamycin GC-MS (3 TMS) - 70eV, Positive | splash10-004i-9821028000-cf121bc5f21859a54a2d | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Clindamycin GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Clindamycin GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin LC-ESI-ITFT , positive-QTOF | splash10-004i-0109100000-37670022935f2d8b670b | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin LC-ESI-ITFT , positive-QTOF | splash10-004i-0000900000-93a1722f96f472875c4a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin LC-ESI-ITFT , positive-QTOF | splash10-004i-0901200000-390e3523bed2d5f929e0 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin LC-ESI-ITFT , positive-QTOF | splash10-004i-0900000000-70466cfb7e0692d073a0 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin LC-ESI-ITFT , positive-QTOF | splash10-004i-0900000000-6bd03c57dadca1290f64 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin LC-ESI-ITFT , positive-QTOF | splash10-004i-0900000000-cd434c8b18380d1a324e | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin LC-ESI-ITFT , positive-QTOF | splash10-004i-2900000000-6c05f4179cb5bb39be52 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin LC-ESI-ITFT , positive-QTOF | splash10-004i-0000900000-94150d67f34bea64e6ad | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin LC-ESI-ITFT , positive-QTOF | splash10-004i-0901200000-8eaa211b21b0d6193e5e | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin LC-ESI-ITFT , positive-QTOF | splash10-004i-0900000000-734d71b0a8760cca4fa1 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin LC-ESI-ITFT , positive-QTOF | splash10-004i-0900000000-dcfb0de2ed3f9a132d0e | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin LC-ESI-ITFT , positive-QTOF | splash10-004i-0900000000-19e29af7279013b527bc | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin LC-ESI-ITFT , positive-QTOF | splash10-004i-2900000000-b410c4ec9eb02ede33ba | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin LC-ESI-ITFT , positive-QTOF | splash10-004i-0109100000-41472a595b36c3659456 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin 30V, Positive-QTOF | splash10-004i-0901200000-3314779cf85f40a0e688 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin 30V, Positive-QTOF | splash10-004i-0901200000-d615b9b4b52a5859a63c | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin 15V, Positive-QTOF | splash10-004i-0000900000-93a1722f96f472875c4a | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin 60V, Positive-QTOF | splash10-004i-0900000000-b712dc39bbf605193fb4 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin 35V, Positive-QTOF | splash10-004i-0109100000-9de33a60fefa24d80490 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin 55V, Positive-QTOF | splash10-004i-0900000000-70466cfb7e0692d073a0 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin 15V, Positive-QTOF | splash10-004i-0000900000-83eb12a1280fe31c6eb2 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Clindamycin 35V, Positive-QTOF | splash10-004i-0109100000-1f91ef342a1063005039 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Clindamycin 10V, Negative-QTOF | splash10-0fka-9456300000-91a0536cf229efc7485e | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Clindamycin 20V, Negative-QTOF | splash10-000b-9312100000-7aa19239c8a21976d0de | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Clindamycin 40V, Negative-QTOF | splash10-00kg-9610000000-4db0493cafa43fc79894 | 2016-08-03 | Wishart Lab | View Spectrum |
| Show more...
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB01190 | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB01190 | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Predicted Concentrations |
---|
| |
Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB01190 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 27005 |
---|
KEGG Compound ID | C06914 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Clindamycin |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 29029 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 3745 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Lamont RF: Can antibiotics prevent preterm birth--the pro and con debate. BJOG. 2005 Mar;112 Suppl 1:67-73. [PubMed:15715599 ]
- Plaisance KI, Drusano GL, Forrest A, Townsend RJ, Standiford HC: Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother. 1989 May;33(5):618-20. [PubMed:2751277 ]
- Klempner MS, Styrt B: Clindamycin uptake by human neutrophils. J Infect Dis. 1981 Nov;144(5):472-9. [PubMed:6171600 ]
- Daum RS: Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med. 2007 Jul 26;357(4):380-90. [PubMed:17652653 ]
|
---|